Pharma companies rank high on Forbes’ most innovative list
Posted: 19 August 2015 |
Alexion, Regeneron,Incyte and BioMarin have all been ranked in the top ten on Forbes magazine’s 2015 list of the “World’s Most Innovative Companies”…
Alexion Pharmaceuticals, Regeneron Pharmaceuticals, Incyte and BioMarin Pharmaceutical have all been ranked in the top ten on Forbes magazine’s 2015 list of the “World’s Most Innovative Companies”.
The companies ranked third, fourth, seventh and tenth, respectively.
Forbes list identifies companies expected to be innovative now and in the future
Rankings are based on what Forbes calls the companies’ “innovation premium,” the difference between their market capitalization and a net present value of cash flows from current businesses. Forbes’ method relies on investors’ ability to identify companies they expect to be innovative now and in the future. The recognition only includes businesses that have at least seven years of financial data and a market value greater than $10 billion, and have measurable investment in research and development.
This is the second consecutive year that BioMarin has received the recognition. The company was previously ranked seventh.
Commenting on appearing on the Forbes list, Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, said, “We are honoured to be recognised by Forbes for the second year in a row for our continued commitment to innovating and advancing treatment for patients with rare conditions. Acknowledgement as one of the ‘World’s Most Innovative Companies’ is a testament to the BioMarin team around the globe who remain focused on the development of therapies that are first or best in class for patients with few, if any, treatment options.”